Status:
UNKNOWN
Trial of Endostar Combined With CHOPT for T Cell Lymphoma
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Collaborating Sponsors:
Simcere Pharmaceutical Co., Ltd
Conditions:
T Cell Lymphoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
Brief Summary
To evaluate the efficacy and safety of Endostar combined with CHOPT in the treatment of T cell lymphoma.
Eligibility Criteria
Inclusion
- Male and female aged 18 to 70 years old.
- Diagnosis of T cell lymphoma according to WHO Classification, without antitumor therapy
- At least 1 measurable tumor mass (greater than 1.5cm in the longest dimension and greater than 1.0 in the short axis)
- Eastern Cooperative Oncology Group status 0-2
- White blood cell≥4.0×109cells/L; Absolute neutrophil count (ANC) ≥1.5×109cells /L; Platelets≥100×109cells/L
- Alanine transaminase (ALT) ≤2×upper limit of normal(ULN); Aspartate transaminase (AST) ≤2×ULN; Total Bilirubin≤1.5×ULN; Creatinine in normal range
Exclusion
- No active central nervous system lymphoma or brain tumor
- Suppurative inflammation,Chronic infection
- Severe heart disease, conclusion: congestive heart failure; uncontrolled cardiac arrhythmia; myocardial infarction; refractory hypertension
- psychiatric history
- Primary cutaneous T cell lymphoma
- Pregnant or lactating women
- Concurrent treatment with another investigational agent
- Accept radiotherapy
Key Trial Info
Start Date :
June 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2015
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT01430013
Start Date
June 1 2011
End Date
December 1 2015
Last Update
November 4 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060